Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Analysis of Antitumor B KAC in Oral Cancer
NCT05452408Phase 1Withdrawn
- Sponsor
- Medical College of Wisconsin
- Start
- Dec 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Antitumor B in squamous cell carcinoma of the oral cavity (OSCC), sponsored by Medical College of Wisconsin. Primary endpoints: Area under the Curve for Saliva at Day 1, Area under the Curve for Plasma at Day 1 and 2 more. Planned start Dec 2026; status: withdrawn.
02
Drugs
Antitumor B
03
Conditions
squamous cell carcinoma of the oral cavity (OSCC)
Beyond the preview
Go deeper on NCT05452408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05452408.